Drug intelligence / Profile preview

gemcitabine + oxaliplatin + 5-fluorouracil + leucovorin

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin. This regimen has been studied for the treatment of locally advanced pancreatic cancer and metastatic colorectal cancer. The drugs are typically administered on a biweekly schedule with specific dosing protocols. Studies have shown moderate activity in advanced pancreatic cancer (median OS 14.5 months) and metastatic colorectal cancer (average OS 22 months). Common side effects include hematological toxicity (neutropenia) and sensory neuropathy.

Other names: GOLF regimen

Targets

RNR (Ribonucleotide reductase)DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on gemcitabine + oxaliplatin + 5-fluorouracil + leucovorin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemcitabine + oxaliplatin + 5-fluorouracil + leucovorin.

Explore the full profile